Search Result
Results for "
respiratory viruses
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
|
|
Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection .
|
-
-
- HY-109004
-
|
BTA-C585
|
RSV
|
Infection
|
|
Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .
|
-
-
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
-
- HY-143495
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
|
-
-
- HY-143496
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
|
-
-
- HY-19874
-
|
|
RSV
|
Infection
|
|
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC50 of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .
|
-
-
- HY-120632
-
|
|
RSV
|
Infection
|
|
BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease .
|
-
-
- HY-120632A
-
|
|
RSV
|
Infection
|
|
BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease .
|
-
-
- HY-126033
-
|
|
HBV
RSV
|
Infection
|
|
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL .
|
-
-
- HY-149267
-
|
|
STING
SARS-CoV
|
Infection
|
|
STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
-
- HY-109072
-
|
|
SARS-CoV
|
Infection
|
|
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2 .
|
-
-
- HY-N12305
-
|
|
RSV
|
Infection
|
|
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL.
|
-
-
- HY-12993
-
RSV604
2 Publications Verification
A-60444
|
RSV
|
Infection
|
|
RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM) .
|
-
-
- HY-N10581
-
|
|
Influenza Virus
|
Infection
|
|
Flutimide is a novel endonuclease inhibitor of influenza virus. Flutimide selectively inhibits endonuclease with an IC50 value of 3 μM. Flutimide shows antiviral activity in cell culture. Flutimide can be used for the research of acute contagious respiratory disease, such as influenza .
|
-
-
- HY-11098
-
|
R170591
|
RSV
|
Infection
|
|
JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg .
|
-
-
- HY-147015
-
|
|
Orthopoxvirus
|
Infection
|
|
HOE961, the diacetate ester proagent of S2242, is active against respiratory cowpox virus infections, is orally active in infection models. Anti-orthopoxvirus activity .
|
-
-
- HY-W013605A
-
|
p-Methoxycinnamaldehyde
|
RSV
|
Infection
|
|
4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL .
|
-
-
- HY-104032
-
|
|
RSV
|
Infection
Metabolic Disease
|
|
Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM . Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV) .
|
-
-
- HY-W011518
-
|
|
Influenza Virus
|
Infection
|
|
2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation .
|
-
-
- HY-W423489
-
|
S-Adenosyl-DL-homocysteine
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
|
-
-
- HY-113806
-
|
(±)-Oleracein E
|
Bacterial
Influenza Virus
Apoptosis
|
Infection
Inflammation/Immunology
|
|
(±)-Trolline ((±)-Oleracein E), an isoquinoline alkaloid, exhibits antibacterial activity against respiratory bacteria and antiviral activity against influenza virus A and B. (±)-Trolline significantly induces HSC apoptosis. (±)-Trolline can be used for the research of liver fibrosis .
|
-
-
- HY-146108
-
|
|
RSV
|
Infection
|
|
RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC50=2.0 nM), but also D486N-mutant F protein (EC50=8.1 nM) .
|
-
-
- HY-143494
-
|
|
RSV
Influenza Virus
|
Infection
|
|
RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
|
-
-
- HY-122587
-
|
|
DNA/RNA Synthesis
RSV
|
Infection
|
|
AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV) .
|
-
-
- HY-12983A
-
|
ALS-008176; ALS-8176
|
RSV
|
Infection
|
|
Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
|
-
-
- HY-148308
-
|
|
RSV
|
Infection
|
|
hRSV-IN-1 is an inhibitor of respiratory syncytial virus (hRSV) .
|
-
-
- HY-158824
-
-
-
- HY-158824A
-
-
-
- HY-11097
-
|
|
RSV
|
Infection
|
|
TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
|
-
-
- HY-20685
-
-
-
- HY-112673
-
|
|
RSV
|
Infection
|
|
RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.
|
-
-
- HY-142009
-
|
|
RSV
|
Infection
|
|
Antiviral agent 10 is an anti-viral agent that can inhibit respiratory syncytial virus (RSV) .
|
-
-
- HY-N10920
-
|
|
RSV
|
Infection
|
|
Genkwanol C, a biflavonoid, has effective antiviral activity against respiratory syncytial virus (RSV) in vitro .
|
-
-
- HY-114784
-
|
Ingamine
|
Influenza Virus
|
Infection
|
|
Ingavirin (Ingamine) exhibits broad spectrum antiviral activities against human respiratory viruses, such as influenza virus A (IVA), human parainfluenza virus (hPIV) and human adenovirus (AdV). Ingavirin exhibits no toxixcity to mice at the dose of 3000 mg/kg .
|
-
-
- HY-112180
-
|
JNJ-678; JNJ-53718678
|
RSV
|
Infection
|
|
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
|
-
-
- HY-12994
-
|
MDT-637
|
RSV
|
Infection
|
|
MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
|
-
-
- HY-12993A
-
|
A-60444 racemate
|
RSV
|
Others
|
|
RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.
|
-
-
- HY-12993B
-
|
A-60444 (R enantiomer)
|
RSV
|
Infection
|
|
RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV.
|
-
-
- HY-20685S
-
|
Palmidrol-d4; Loramine P 256-d4
|
Influenza Virus
Endogenous Metabolite
|
Infection
|
|
Palmitoylethanolamide-d4 is the deuterium labeled Palmitoylethanolamide. Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
|
-
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection .
|
-
-
- HY-119375
-
|
|
Bacterial
|
Infection
|
|
Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively .
|
-
-
- HY-111296
-
|
|
RSV
|
Infection
|
|
YM 53403 is an anti-respiratory syncytial virus (RSV) agent, with an EC50 of 0.20 μM. YM 53403 potently inhibits the replication of RSV strains belonging to both A and B subgroups .
|
-
-
- HY-12983
-
|
|
RSV
|
Infection
|
|
ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
|
-
-
- HY-N2092
-
|
|
Bacterial
|
Infection
Cancer
|
|
Atractylodinol, an antimicrobial, is a PRRSV (porcine reproductive and respiratory syndrome virus) inhibitor. Atractylodinol inhibits TGF-β receptor I recycling by binding to vimentin (KD of 454 nM) and inducing the formation of filamentous aggregates .
|
-
-
- HY-142645
-
|
|
RSV
|
Infection
|
|
RSV-IN-2 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins (wild-type, EC50 = 0.27 nM; D486N-mutant, EC50 = 0.70 nM).
|
-
-
- HY-102038
-
|
|
RSV
|
Infection
|
|
PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM) .
|
-
-
- HY-10367A
-
|
CI-1033 dihydrochloride; PD-183805 dihydrochloride
|
EGFR
Orthopoxvirus
|
Infection
Cancer
|
|
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice .
|
-
-
- HY-15511
-
|
Tyrphostin 9; Malonoben
|
VEGFR
Influenza Virus
PDGFR
|
Infection
Cancer
|
|
Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti-influenza virus activities.
|
-
-
- HY-14460
-
|
|
FLAP
|
Inflammation/Immunology
|
|
AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .
|
-
-
- HY-P10245
-
|
|
RSV
|
Inflammation/Immunology
|
|
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
|
-
- HY-10367
-
Canertinib
Maximum Cited Publications
9 Publications Verification
CI-1033; PD-183805
|
EGFR
Orthopoxvirus
|
Infection
Cancer
|
|
Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice .
|
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research .
|
-
- HY-109142
-
|
AK0529; RO-0529
|
RSV
|
Infection
|
|
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
|
-
- HY-13859
-
|
L-FMAU
|
HBV
DNA/RNA Synthesis
Orthopoxvirus
|
Infection
|
|
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
|
-
- HY-N8448
-
|
Macroantoin F
|
RSV
|
Infection
|
|
3,4-Di-O-caffeoyl quinic acid methyl ester (Macroantoin F) is a dicaffeoyl derivative isolated from the rhizome of Elephantopus scaber Linn. 3,4-Di-O-caffeoyl quinic acid methyl ester exhibited in vitro antiviral activity against respiratory syncytial virus (< a href=" " class="link-product" target="_blank">RSV) with an IC50 value of 0.78 μg/mL .
|
-
- HY-109035
-
|
SB9200; GS-9992
|
HCV
HBV
|
Infection
|
|
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
|
-
- HY-12283
-
|
PST 2238
|
Na+/K+ ATPase
RSV
|
Cardiovascular Disease
|
|
Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
|
-
- HY-154968
-
|
|
RSV
|
Infection
|
|
RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC50=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
|
-
- HY-115574
-
|
|
RSV
|
Infection
|
|
RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
|
-
- HY-145119AS
-
|
JT001; VV116; GS-621763-d1 hydrobromide
|
SARS-CoV
RSV
Influenza Virus
|
Infection
|
|
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
|
-
- HY-100943
-
|
SQ 10643
|
5-HT Receptor
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro .
|
-
- HY-149648
-
|
|
RSV
|
Infection
|
|
JNJ-8003 is a potent inhibitor of RSV Polymerase. JNJ-8003 inhibits nucleotide polymerization of RNA transcription and replication at the early stages .
|
-
- HY-151269A
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151269
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151276
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC50 value of 3.0 μM .
|
-
- HY-151278
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC50 value of 6.9 μM .
|
-
- HY-151276A
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM .
|
-
- HY-151278A
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC50s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC50 value of 6.9 μM .
|
-
- HY-151271A
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM .
|
-
- HY-151274
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-151271
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC50 value of 6.5 μM .
|
-
- HY-151274A
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM .
|
-
- HY-P0012
-
|
Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-P0012A
-
|
Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-P0012R
-
|
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil (Standard) is the analytical standard of Aviptadil. This product is intended for research and analytical applications. Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-163532
-
|
|
Sirtuin
|
Infection
|
|
FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC50 of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0012
-
|
Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-P0012A
-
|
Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
-
- HY-P10245
-
|
|
RSV
|
Inflammation/Immunology
|
|
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
|
-
- HY-P0012R
-
|
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Aviptadil (Standard) is the analytical standard of Aviptadil. This product is intended for research and analytical applications. Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
|
|
Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection .
|
-
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection .
|
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-145119AS
-
|
|
|
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
|
-
-
- HY-20685S
-
|
|
|
Palmitoylethanolamide-d4 is the deuterium labeled Palmitoylethanolamide. Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
